Steel Peak Wealth Management LLC acquired a new stake in Eli Lilly And Co (NYSE:LLY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 4,063 shares of the company’s stock, valued at approximately $534,000.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Point72 Asset Management L.P. purchased a new position in shares of Eli Lilly And Co in the third quarter valued at about $101,403,000. BlackRock Inc. increased its position in shares of Eli Lilly And Co by 1.5% in the second quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock valued at $6,866,670,000 after acquiring an additional 898,845 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Eli Lilly And Co by 10.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 6,442,803 shares of the company’s stock valued at $720,499,000 after acquiring an additional 628,267 shares during the period. PGGM Investments increased its position in shares of Eli Lilly And Co by 1,490.6% in the fourth quarter. PGGM Investments now owns 545,015 shares of the company’s stock valued at $71,631,000 after acquiring an additional 510,751 shares during the period. Finally, California Public Employees Retirement System increased its position in shares of Eli Lilly And Co by 13.1% in the third quarter. California Public Employees Retirement System now owns 4,096,921 shares of the company’s stock valued at $458,159,000 after acquiring an additional 474,687 shares during the period. Hedge funds and other institutional investors own 76.28% of the company’s stock.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction dated Thursday, January 9th. The shares were sold at an average price of $135.79, for a total transaction of $29,873,800.00. Following the sale, the insider now owns 114,136,224 shares of the company’s stock, valued at $15,498,557,856.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Myles O’neill sold 25,000 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the sale, the senior vice president now directly owns 40,424 shares in the company, valued at approximately $4,850,880. The disclosure for this sale can be found here. Insiders have sold 1,609,483 shares of company stock worth $206,714,535 in the last three months. 0.11% of the stock is currently owned by insiders.

Shares of LLY traded down $0.67 during trading hours on Friday, reaching $141.13. 147,961 shares of the company traded hands, compared to its average volume of 3,665,721. The company’s fifty day moving average price is $138.38 and its two-hundred day moving average price is $119.86. The company has a market capitalization of $136.38 billion, a price-to-earnings ratio of 16.13, a price-to-earnings-growth ratio of 1.61 and a beta of 0.21. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09. Eli Lilly And Co has a 12 month low of $101.36 and a 12 month high of $147.87.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Thursday, January 30th. The company reported $1.73 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.21. The firm had revenue of $6.11 billion for the quarter, compared to analyst estimates of $5.92 billion. Eli Lilly And Co had a net margin of 37.27% and a return on equity of 188.01%. The company’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.33 EPS. On average, analysts expect that Eli Lilly And Co will post 6.76 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 14th will be paid a dividend of $0.74 per share. The ex-dividend date is Thursday, February 13th. This represents a $2.96 annualized dividend and a yield of 2.10%. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.65. Eli Lilly And Co’s payout ratio is presently 42.72%.

A number of research firms have issued reports on LLY. Cantor Fitzgerald restated a “buy” rating and issued a $156.00 price objective on shares of Eli Lilly And Co in a research report on Monday, February 3rd. Morgan Stanley raised shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $116.00 to $150.00 in a research note on Wednesday, December 18th. They noted that the move was a valuation call. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly And Co from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th. Argus lifted their target price on shares of Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a research note on Monday, December 30th. Finally, Mizuho assumed coverage on shares of Eli Lilly And Co in a research note on Wednesday, February 5th. They set a “neutral” rating and a $148.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $137.36.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: Google Finance Portfolio

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.